ENDRA Life Sciences Inc.
NDRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4 | $3 | $2 | $3 |
| - Cash | $1 | $2 | $2 | $3 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $4 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.1 | -1.71 | -1.86 | -7.73 |
| % Growth | -22.8% | 8.1% | 75.9% | – |
| Operating Cash Flow | -$1 | -$1 | -$1 | -$2 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$1 | -$1 | -$1 | -$2 |